Octreotide
Octreotide is an active ingredient of the class «hypothalamic hormones».
Chemical compound
What it is used for
- Carcinoid tumor
- Neuroendocrine carcinoma
- Pituitary carcinoma
- Follicular adenoma
- Acromegaly
- Pancreatic cancer
- Carcinoid syndrome
- Neoplasm
- Metastasis
Sandostatin Injection is a somatostatin analogue indicated: Acromegaly: To reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation…
Oczyesa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.
How it works
- Somatostatin receptor agonist
Class: hypothalamic hormones
Common side effects
The following clinically significant adverse reactions are described elsewhere in the labeling: Complete Atrioventricular Block Cholelithiasis and Complications of Cholelithiasis Hyperglycemia and Hypoglycemia Thyroid Function Abnormalities Steatorrhea and Malabsorption of Dietary Fats Changes in Vitamin B12 Levels…
Who should not take it
Sensitivity to this drug or any of its components. Sensitivity to this drug or any of its components.
Pregnancy and breastfeeding
The limited data with Sandostatin Injection in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage.
Interactions
- Bromocriptine
- Ciclosporin
- Glucagon
- Insulin aspart
- Insulin degludec
- Insulin detemir
- Insulin glargine
- Insulin human
- Insulin lispro
- Repaglinide
Brand names
United States
Bynfezia PEN · Mycapssa · Sandostatin · Sandostatin LAR
European Union
Oczyesa
Canada
Octreotide Acetate Omega · Octreotide Depot · Oczyesa XR · Sandostatin LAR
Other trade names
Octreotide acetate preservative free
Approval status
- US Food and Drug Administration
- prescription · since 1988
- European Medicines Agency
- authorised · since 2025
- Health Canada
- prescription · marketed
- First approval anywhere
- 1988
Codes
- ATC
- H01CB02
- RxNorm CUI
- 7617
- ChEMBL
- CHEMBL1680
- PubChem CID
- 448601
- UNII
- RWM8CCW8GP
- Wikidata
- Q419935
Frequently asked questions
What is Octreotide used for?
Octreotide is used for: Carcinoid tumor, Neuroendocrine carcinoma, Pituitary carcinoma, Follicular adenoma, Acromegaly, Pancreatic cancer, Carcinoid syndrome, and Neoplasm.
What kind of medicine is Octreotide?
Octreotide is an active ingredient of the class «hypothalamic hormones».
What are the brand names of Octreotide?
Brand names of Octreotide include Bynfezia PEN, Mycapssa, Sandostatin, Sandostatin LAR, Oczyesa, Octreotide Acetate Omega, Octreotide Depot, and Oczyesa XR.
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)